Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Identification of type-specific anticancer histone deacetylase inhibitors: road to success

(2010) Nighat Noureen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The promises and pitfalls of epigenetic therapies in solid tumours

(2009) Janet S. Graham et al.   EUROPEAN JOURNAL OF CANCER

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

(2008) Jung-Hyun Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

(2008) Nagma Khan et al.   BIOCHEMICAL JOURNAL

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

(2008) W Weichert et al.   BRITISH JOURNAL OF CANCER

Histone Deacetylase Inhibitors: From Bench to Clinic

(2008) Marielle Paris et al.   JOURNAL OF MEDICINAL CHEMISTRY

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

(2008) M. Fournel et al.   MOLECULAR CANCER THERAPEUTICS